噬菌体特异性抗体对噬菌体治疗的影响
作者:
基金项目:

国家自然科学基金(81872540);上海市第一人民医院优秀医学青年人才A类计划(06N1702002)


Phage-specific antibodies impair its antibacterial efficacy
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [44]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论
    摘要:

    噬菌体治疗已成为当下防控泛耐药细菌感染的重要选择。噬菌体作为含有蛋白和核酸组分的病毒颗粒,经不同途径进入机体后,均能诱导机体产生特异性中和抗体。本文就噬菌体治疗过程中诱导机体产生的特异性中和抗体、抗体的产生规律、抗体是否影响噬菌体治疗疗效,以及可能克服抗体影响噬菌体治疗的方法等进行论述。噬菌体颗粒诱导特异性中和抗体的产生及血清抗噬菌体活性的水平与噬菌体的给予途径、类型和剂量、结构蛋白以及宿主的免疫状态、感染部位、治疗持续时间等均有关,且不同类型抗体产生时间和强度不同,均能中和噬菌体从而降低其杀菌效果。这提示在使用噬菌体治疗耐药细菌感染时,需要探索克服噬菌体中和抗体干扰的方法,或针对机体不同状态及感染类别制定相应的治疗策略,降低诱导机体产生噬菌体特异性中和抗体的风险,以获得最佳治疗效果。

    Abstract:

    Phage therapy has become an important choice to control multi-drug-resistant bacteria. As viruses containing both proteins and nucleic acids, phages can induce the generation of specific neutralizing antibodies in the host. This article reviews the phage-specific neutralizing antibodies during phage therapy, particularly the law of neutralizing antibody generation, the influence of the antibodies on phages' antibacterial efficacy, and the countermeasures against the influence. In summary, phage particles do induce the generation of specific neutralizing antibodies in the body, and the level of antibodies is correlated with the usage, type, dosage, and structural proteins of phages, the immunity of the host, and infected sites, treatment duration, etc. The generation time and yield are different among different types of antibodies. They all can neutralize phages and reduce the antibacterial efficacy. Therefore, in phage therapy, measures for controlling the neutralizing antibodies or strategies for different statuses/types of infection should be taken to reduce the generation of neutralizing antibodies and achieve the best therapeutic efficacy.

    参考文献
    [1] Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy, 2017, 61(10):e00954-e00917.
    [2] Bao J, Wu NN, Zeng YG, Chen LG, Li LL, Yang L, Zhang YY, Guo MQ, Li LS, Li J, Tan DM, Cheng MJ, Gu JM, Qin JH, Liu JZ, Li SR, Pan GQ, Jin X, Yao BX, Guo XK, Zhu TY, Le S. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerging Microbes& Infections, 2020, 9(1):771-774.
    [3] Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, de Corte P, Rose T, Jennes S, Zizi M, de Vos D, Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 2009, 4(3):e4944.
    [4] Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans:results of a phase I safety trial. Journal of Wound Care, 2009, 18(6):237-238, 240-243.
    [5] Inchley CJ. The actvity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clinical and Experimental Immunology, 1969, 5(1):173-187.
    [6] Chun KS, Kang YJ, Lee JY, Nguyen M, Lee B, Lee R, Jo HH, Allen E, Chen H, Kim J, Yu L, Ni XY, Lee K, Jeong H, Lee J, Park Y, Chung HU, Li AW, Lio PA, Yang AF, Fishbein AB, Paller AS, Rogers JA, Xu S. A skin-conformable wireless sensor to objectively quantify symptoms of pruritus. Science Advances, 2021, 7(18):eabf9405.
    [7] Srivastava AS, Kaido T, Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. Journal of Virological Methods, 2004, 115(1):99-104.
    [8] Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N,Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaś A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłosowska D. Phage as a modulator of immune responses:practical implications for phage therapy. Advances in Virus Research, 2012, 83:41-71.
    [9] Krut O, Bekeredjian-Ding I. Contribution of the immune response to phage therapy. Journal of Immunology:Baltimore, Md:1950, 2018, 200(9):3037-3044.
    [10] Herelle FD, Smith GH. The bacteriophage, its rôle in immunity.[M]. Baltimore:Williams& Wilkins company, 1922.
    [11] Uhr JW, Finkelstein MS, Baumann JB. Antibody formation. III. The primary and secondary antibody response to bacteriophage phi-X 174 in Guinea pigs. The Journal of Experimental Medicine, 1962, 115:655-670.
    [12] Uhr JW, Finkelstein MS. Antibody formation. IV. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage phi-X 174. The Journal of Experimental Medicine, 1963, 117:457-477.
    [13] Hájek P. Neutralization of bacterial viruses by antibodies of young animals. 3. The development of the avidity of 19S and 7S neutralizing antibodies in the course of primary and secondary response in young rabbits immunized with Phi-X 174 bacteriophage. Folia Microbiologica, 1970, 15(1):9-16.
    [14] Ching YC, Davis SD, Wedgwood RJ. Antibody studies in hypogammaglobulinemia. The Journal of Clinical Investigation, 1966, 45(10):1593-1600.
    [15] Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. The Journal of Clinical Investigation, 1971, 50(12):2559-2568.
    [16] Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, Liu GQ, Ochs HD. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi-X 174 in asymptomatic HIV-1 infected patients. AIDS:London, England, 2000, 14(4):F55-F62.
    [17] Sullivan J, Schiffman G, Miser J, Ochs H, Hammerschlag M, Vichinsky E, Wedgwood R. Immune response after splenectomy. The Lancet, 1978, 311(8057):178-181.
    [18] Nonoyama S, Hollenbaugh D, Aruffo A, Ledbetter JA, Ochs HD. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. The Journal of Experimental Medicine, 1993, 178(3):1097-1102.
    [19] Shearer WT, Lugg DJ, Rosenblatt HM, Nickolls PM, Sharp RM, Reuben JM, Ochs HD. Antibody responses to bacteriophage φX-174 in human subjects exposed to the Antarctic winter-over model of spaceflight. Journal of Allergy and Clinical Immunology, 2001, 107(1):160-164.
    [20] Van Belleghem JD, D\u0105browska K, Vaneechoutte M, Barr JJ, Bollyky PL. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses, 2018, 11(1):10.
    [21] Naghizadeh M, Karimi Torshizi MA, Rahimi S, Engberg RM, Sørensen Dalgaard T. Effect of serum anti-phage activity on colibacillosis control by repeated phage therapy in broilers. Veterinary Microbiology, 2019, 234:61-71.
    [22] Hodyra-Stefaniak K, Kaźmierczak Z, Majewska J, Sillankorva S, Miernikiewicz P, Międzybrodzki R, Górski A, Azeredo J, Lavigne R, Lecion D, Nowak S, Harhala M, Waśko P, Owczarek B, Gembara K, Dąbrowska K. Natural and induced antibodies against phages in humans:induction kinetics and immunogenicity for structural proteins of PB1-related phages. PHAGE, 2020, 1(2):91-99.
    [23] Gembara K, Dąbrowska K. Phage-specific antibodies. Current Opinion in Biotechnology, 2021, 68:186-192.
    [24] Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage therapy in bacterial infections treatment:one hundred years after the discovery of bacteriophages. Current Microbiology, 2017, 74(2):277-283.
    [25] Archana A, Patel PS, Kumar R, Nath G. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model. Virusdisease, 2021, 32(1):38-45.
    [26] Chang CC, Winter AJ, Norcross NL. Immune response in the bovine mammary gland after intestinal, local, and systemic immunization. Infection and Immunity, 1981, 31(2):650-659.
    [27] Dąbrowska K, Miernikiewicz P, Piotrowicz A, Hodyra K, Owczarek B, Lecion D, Kaźmierczak Z, Letarov A, Górski A. Immunogenicity studies of proteins forming the T4 phage head surface. Journal of Virology, 2014, 88(21):12551-12557.
    [28] Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, Drab M, Jończyk-Matysiak E, Lecion D, Kaźmierczak Z, Beta W, Majewska J, Harhala M, Bubak B, Kłopot A, Górski A, Dąbrowska K. Mammalian host-versus-phage immune response determines phage fate in vivo. Scientific Reports, 2015, 5:14802.
    [29] Huff W, Huff G, Rath N, Balog J, Donoghue A. Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poultry Science, 2002, 81(10):1486-1491.
    [30] Huff W, Huff G, Rath N, Balog J, Donoghue A. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poultry Science, 2003, 82(7):1108-1112.
    [31] Huff WE, Huff GR, Rath NC, Donoghue AM. Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poultry Science, 2010, 89(5):895-900.
    [32] Majewska J, Beta W, Lecion D, Hodyra-Stefaniak K, Kłopot A, Kaźmierczak Z, Miernikiewicz P, Piotrowicz A, Ciekot J, Owczarek B, Kopciuch A, Wojtyna K, Harhala M, Mąkosa M, Dąbrowska K. Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses, 2015, 7(8):4783-4799.
    [33] Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. Journal of General Microbiology, 1987, 133(5):1127-1135.
    [34] Uhr JW, Finkelstein S, Franklin EC. Antibody response to bacteriophage phi-X-174 in non-mammalian vertebrates. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine:New York, N Y, 1962, 111:13-15.
    [35] Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, Mican J, Siegel JP, Sneller M, Lane HC. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. The Journal of Infectious Diseases, 2000, 182(2):435-441.
    [36] Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Archivum Immunologiae et Therapiae Experimentalis, 1987, 35(5):553-561.
    [37] Łusiak-Szelachowska M,Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Letkiewicz S, Fortuna W, Rogóż P, Szufnarowski K, Jończyk-Matysiak E, Olchawa E, Walaszek KM, Górski A. Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbiology, 2017, 12:109-117.
    [38] Dąbrowska K. Phage therapy:what factors shape phage pharmacokinetics and bioavailability?Systematic and critical review. Medicinal Research Reviews, 2019, 39(5):2000-2025.
    [39] Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally:a safety test of phage therapy. Antimicrobial Agents and Chemotherapy, 2005, 49(7):2874-2878.
    [40] Ackermann HW. Phage classification and characterization. Methods in Molecular Biology:Clifton, N J, 2009, 501:127-140.
    [41] Salmond GPC, Fineran PC. A century of the phage:past, present and future. Nature Reviews Microbiology, 2015, 13(12):777-786.
    [42] Barr JJ. A bacteriophages journey through the human body. Immunological Reviews, 2017, 279(1):106-122.
    [43] Górski A, Wazna E, Dabrowska BW, Dabrowska K, Switała-Jeleń K, Miedzybrodzki R. Bacteriophage translocation. FEMS Immunology and Medical Microbiology, 2006, 46(3):313-319.
    [44] Hájek P. Properties of natural 19S antibodies in normal pig serum against the phi x 174 and T2 phages. Folia Microbiologica, 1967, 12(6):551-556.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

仲丽雯,郭晓奎,姚玉峰,崔泽林. 噬菌体特异性抗体对噬菌体治疗的影响[J]. 微生物学报, 2022, 62(7): 2441-2454

复制
分享
文章指标
  • 点击次数:539
  • 下载次数: 1193
  • HTML阅读次数: 1908
  • 引用次数: 0
历史
  • 收稿日期:2021-10-18
  • 最后修改日期:2021-12-23
  • 在线发布日期: 2022-07-06
  • 出版日期: 2022-07-04
文章二维码